Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating
摩根士丹利将Cabaletta Bio的目标股价从28美元下调至25美元,因为美国食品药品管理局正在调查CAR-T细胞疗法中的T细胞恶性肿瘤,维持增持评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册